Data- driven precision medicine has been touted as the next frontier in oncology. Every day, millions of people across the globe are diagnosed with different types of cancer. The disease has become one of the biggest contributors to high mortality rates in the modern society. With more and more cases of cancer being reported, doctors are finding themselves in a situation where they need to comb through mountains of data for them to recommend the best therapies.
Eric Lefkosfky became aware of the challenges that oncologists faced in their work when he took his wife for treatment. A loved one to the businessman had been diagnosed with breast cancer, and she needed personalized therapies. It was at this moment that Eric discovered the limited amount of data that is available for oncologists to draw analyses and trends before they can recommend treatment. From this realization, Eric decided to come up with a technological solution that will avail genomic and therapeutic data from cancer patients so that doctors can draw patterns that will enable them to administer personalized cancer treatment solutions and learn more about Eric.
Tempus is a company that samples, collects and aggregates data from a cancer patient with the aim of drawing analytics that will help doctors in medical research to come up with more effective therapies for cancer. For a long time, personalized healthcare has been a preserve of the elite. Tempus is working to ensure that precision medicine can be made affordable to the average man. Unlike the existing cancer therapies that attack the cancer cells, Eric Lefkofsky’s company intends to come up with solutions that fight the disease at the molecular level.
Eric Lefkofsky was brought up in Southfield, Michigan. The entrepreneur graduated from the renowned University of Michigan. He earned his degree in laws from the Law School of the same institution. The business leader has also lived in Chicago for several years. He is best known in the corporate circles as the co-founder of Tempus and Groupon.
Apart from being committed to the advancement of research in medicine, Eric Lefkofsky is also involved in philanthropy. The seasoned entrepreneur has also been successful in the halls of academia. He currently holds the position of adjunct professor at the Business School of the University of Chicago and more information click here.
More Visit: http://chicago.curbed.com/2015/1/6/10005148/groupon-ceo-eric-lefkofsky-the-man-behind-195m-home-sale
There have been many advances in cancer, but it has been hard for all oncologists to get them and to be able to use them for different situations because of all of the issues that come along with the experiences that they have. It has been a struggle for most people, but it has not always worked out because of the issues that come along with a lack of communication in oncology field. Mikhail Blagosklonny knew this because he is a part of the oncology field and because he worked hard to be able to show people what they can do to make their lives better while they are battling cancer.One thing that he always hoped for in the field was better communication. He wanted there to be some type of peer review or publication that would make things better for doctors to learn more about cancer what was going on or what they could do to help their patients.
He knew that other oncology specialists had them, but he also knew that he wanted to be able to make sure that he could help his own type of patients out with the issues that they had. For Mikhail Blagosklonny to do this, he had to be sure that the oncologists in the country could connect with each other.The answer that he was looking for came in the form of a peer review publication. Since there wasn’t one that was geared specifically toward oncologists, he decided to just start one on his own. He tried his best to start Oncotarget and he knew that he would be able to make a difference with the publication. For that reason, he did his best to show people what they were going to get from it so that they could help their patients in the same way that other oncologists were able to help their own patients.
Out of all of the things that Mikhail Blagosklonny was doing, he knew that he could try his best and show people what would make a difference. He tries to always include new advancements into the Oncotarget publication, but he sometimes has to get other doctors on board so that he will be able to help even more people. Not just oncologists can come up with treatment for cancer and he knows that the help of other doctors will be something that he can enjoy.As things have gotten better for Mikhail Blagosklonny and the publication has grown, he has been showing people what they can do and how they can get more out of the situations that they are in. This is what has given him a chance to experience more and to try more opportunities out with the things that are going on. It has also given him a chance to grow the industry and make it better than what it was in the past for cancer patients to feel better and to be able to be healed from their disease that they are battling.
When Eric Lofkosfky left Groupon, he began building up the newly launched firm, Tempus. Tempus is a modern day cancer treatment facility that uses high-tech devices to diagnose and treat cancer. Tempus’ medical practitioners use real-time and customized data–based therapy machines to analyze each patient’s genetic makeup. They then use the results to determine the best molecular therapies for the particular cancer type ailing the candidate. The technology helps patients understand a patient’s tumor better to create a most suitable medication using massive amounts of statistical genomic data. The company separated itself from its parent company LightBank, which is also owned by Eric. Eric is currently serving as Tempus’ president and believes that the firm can develop next breakthrough in medicine world.
On July 18th, 2016, Eric wrote about how data collection and artificial intelligence propel the society forward in medicine. He explained the various ways that health care has reached milestones in developing new technology. In 2003, Tempus produced the first human genome with over 100 million dollars. After only 13 years they, processed the same procedure with only 5000 dollars. He estimates that in a few more years, it will be available for just a few hundred dollars. The system allows physicians to tailor the necessary treatments medicine rations for all cancers. Currently, Tempus has an employee capacity of 29, including the former director of products At HighGround, Hunter Lane and Lightbank’s former vice president, Ryan Fukushima.
Eric and his wife Liz are regular donors to the cancer research treatment movement through their organization Lofkosfky Family Foundation. In November 2016, they contributed 1 million dollars to the Robert Lurie Comprehensive Cancer Center of the Northwestern University. In October of the same year, they donated $500,000 to the development of immunotherapy gastric cancer at the Stanford University. They contributed 1.2 million dollars to cancer research at the University of Michigan. The New York Weill Cornell Medicine Foundation received $250,000 from the couple to treat breast cancer. Eric and his wife are members of The Giving Pledge and have a pledge to donate half of their wealth to philanthropy at the end of their lifetimes.
for more info: www.tempus.com/about-us/